One and a half months after starting consumer marketing, Terclara® has reached a market leading position, both in value and units, with a 36% market share in value and 31% market share in units in April. Additionally, the introduction of Terclara® has led to a 52% growth in the total market compared to the same period last year.[1]
Terclara® has been available on Swedish pharmacy shelves since February this year. In parallel with the pharmacies filling up the shelves, work was ongoing in February and March to inform physicians and pharmacists about the unique benefits of Terclara®. Subsequently, the focus shifted to the end consumer, including digital marketing from mid-March and TV advertising starting
"I am very pleased with the launch together with our partner Allderma. Terclara® is now available for those who want to begin the journey towards attractive, fungus-free nails before sandal season and summer vacation. It is an achievement to quickly reach a market-leading position, and the team in Allderma once again demonstrates that they are an excellent partner in our home market." says
For additional information, please contact:
About this information
The information was submitted for publication, through the agency of the contact person set out above, on
About MOB-015 and Onychomycosis
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products.
MOB-015 is an in-house developed topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. MOB-015 has been granted marketing authorization in 13 countries and is launched during spring 2024 in
About
[1] Source: IQVIA MIDAS, Pharmacy Sell-Out data,
https://news.cision.com/moberg-pharma/r/terclara-is-the-market-leader-in-sweden,c3984099
https://mb.cision.com/Main/1662/3984099/2806246.pdf
(c) 2024 Cision. All rights reserved., source